News & Updates

Show Multimedia Only

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

Does using GLP-1 RAs induce suicide in T2D patients?

08 Mar 2025 by

Patients with type 2 diabetes (T2D) who use glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) appear to have no increased risk of suicidality when compared with the use of dipeptidyl peptidase-4 inhibitors (DPP-4is) or sodium-glucose cotransporter-2 inhibitors (SGLT-2is), a study has found.

Does using GLP-1 RAs induce suicide in T2D patients?

08 Mar 2025

Cabozantinib plus ipilimumab/nivolumab fails to meet efficacy target in thyroid cancer

07 Mar 2025

Treatment with cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) results in low objective response rates (ORRs) and a high rate of grade ≥3 treatment-related adverse events (AEs) among patients with previously treated advanced differentiated thyroid cancer, reveals a recent study.

Cabozantinib plus ipilimumab/nivolumab fails to meet efficacy target in thyroid cancer

07 Mar 2025

Adrenalectomy extends survival in metastatic adrenocortical carcinoma

06 Mar 2025

Undergoing adrenalectomy may help reduce mortality in patients with metastatic adrenocortical carcinoma (mACC), particularly in those with exposure to systemic therapy and those with lung-only metastases, according to a study.

Adrenalectomy extends survival in metastatic adrenocortical carcinoma

06 Mar 2025

Two- vs one-bag method: Which works best for DKA treatment?

06 Mar 2025

Implementation of the two-bag method for the management of diabetic ketoacidosis (DKA) has improved safety and efficacy outcomes when compared with the one-bag method, according to a study.

Two- vs one-bag method: Which works best for DKA treatment?

06 Mar 2025

GLP-1 receptor agonists reduce more fat than muscle mass

05 Mar 2025 by

Glucagon-like peptide-1 (GLP-1) receptor agonists likely induce weight loss by reducing more fat mass than muscle mass, a research team from the University of Hong Kong (HKU) has found.

GLP-1 receptor agonists reduce more fat than muscle mass

05 Mar 2025

GLP-1RAs lower depression risk in older adults with T2D

03 Mar 2025

The incidence of depression among older adults with type 2 diabetes is low, and the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) helps reduce the risk of depression relative to dipeptidyl peptidase-4 inhibitors (DPP4is), but not sodium–glucose cotransporter-2 inhibitors (SGLT2is).

GLP-1RAs lower depression risk in older adults with T2D

03 Mar 2025

Five BP readings establish BP variability to predict cardiac risk in diabetics

03 Mar 2025

Long-term visit-to-visit variability in blood pressure (BP) may be used to predict cardiovascular outcomes in people with diabetes, suggests a study. At least five BP measurements are necessary to effectively estimate intraindividual VVV and assess cardiovascular risk.

Five BP readings establish BP variability to predict cardiac risk in diabetics

03 Mar 2025

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

03 Mar 2025 by

Combined use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and pioglitazone may be a potentially useful strategy to ameliorate metabolic dysfunction–associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), according to a real-world study conducted by researchers from the University of Hong Kong and Queen Mary Hospital (QMH).

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

03 Mar 2025

Weight loss plays crucial role in diabetes remission

02 Mar 2025

Bodyweight loss appears to have a strong, independent dose-response association with type 2 diabetes (T2D) remission among people with obesity or overweight, according to the results of a meta-analysis.

Weight loss plays crucial role in diabetes remission

02 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Does using GLP-1 RAs induce suicide in T2D patients?

Does using GLP-1 RAs induce suicide in T2D patients?

Cabozantinib plus ipilimumab/nivolumab fails to meet efficacy target in thyroid cancer

Cabozantinib plus ipilimumab/nivolumab fails to meet efficacy target in thyroid cancer

Adrenalectomy extends survival in metastatic adrenocortical carcinoma

Adrenalectomy extends survival in metastatic adrenocortical carcinoma

Two- vs one-bag method: Which works best for DKA treatment?

Two- vs one-bag method: Which works best for DKA treatment?

GLP-1 receptor agonists reduce more fat than muscle mass

GLP-1 receptor agonists reduce more fat than muscle mass

GLP-1RAs lower depression risk in older adults with T2D

GLP-1RAs lower depression risk in older adults with T2D

Five BP readings establish BP variability to predict cardiac risk in diabetics

Five BP readings establish BP variability to predict cardiac risk in diabetics

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

Weight loss plays crucial role in diabetes remission

Weight loss plays crucial role in diabetes remission